Skip to main content Skip to section navigation Skip to footer
SCYNEXIS, Inc. SCYNEXIS, Inc.
  • About Us
    • Our Mission
    • Leadership
    • Partnerships
    • Careers
    • Contact Us
  • Our Science
    • Ibrexafungerp
    • Life-threatening Infections
    • Community Infections
    • Pipeline
    • Publications and Presentations
  • Our Product
  • News
    • News
    • Events
  • Careers
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Info
    • SEC Filings
    • Governance

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
    • Tear Sheet
  • Financial Info
    • Overview
    • Financial Results
    • Key Ratios
    • Investor Calculator
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Investor Calculator
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
    • Quarterly Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Apr 06, 2016 9:20am EDT

SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis

Mar 07, 2016 8:37am EST

SCYNEXIS, Inc. Reports Full Year 2015 Financial Results and Provides Company Update

Feb 29, 2016 5:30pm EST

SCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference

Feb 03, 2016 9:05am EST

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Jan 28, 2016 9:05am EST

SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections

Dec 01, 2015 5:09pm EST

SCYNEXIS, Inc. Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis

Nov 13, 2015 9:03am EST

SCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results and Provides Company Update

Nov 12, 2015 8:30am EST

SCYNEXIS, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating Intravenous Formulation of SCY-078

Nov 02, 2015 5:25pm EST

SCYNEXIS Appoints Eric Francois as Chief Financial Officer

Oct 07, 2015 4:30pm EDT

SCYNEXIS Appoints Rajeshwar Motheram as Vice President, Pharmaceutical Development

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • …
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Scynexis
1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
Facebook Twitter Linkedin
  • Patents
  • Expanded Access
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2025 SCYNEXIS, Inc. All Rights Reserved.